SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
+2.74%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$611M
AUM Growth
+$611M
(-0.38%)
Cap. Flow
-$234M
Cap. Flow
% of AUM
-38.33%
Top 10 Holdings %
Top 10 Hldgs %
32.55%
Holding
133
New
19
Increased
27
Reduced
41
Closed
21
Top Buys
| 1 |
Teva Pharmaceuticals
TEVA
|
$24.2M |
| 2 |
Nova
NVMI
|
$10.8M |
| 3 |
Viking Therapeutics
VKTX
|
$8.42M |
| 4 |
Check Point Software Technologies
CHKP
|
$7.75M |
| 5 |
Biohaven
BHVN
|
$6.66M |
Top Sells
| 1 |
CYBN
Cybin
CYBN
|
$219M |
| 2 |
Kezar Life Sciences
KZR
|
$14.3M |
| 3 |
Salesforce
CRM
|
$8.64M |
| 4 |
Cytokinetics
CYTK
|
$8.44M |
| 5 |
Praxis Precision Medicines
PRAX
|
$7.54M |
Sector Composition
| 1 | Healthcare | 71.97% |
| 2 | Technology | 19.72% |
| 3 | Consumer Discretionary | 3.62% |
| 4 | Communication Services | 3.05% |
| 5 | Utilities | 0.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Teva Pharmaceuticals
TEVA
$21.1B
| $38.4M | 6.11% | 2,130,216 +1,340,800 | +170% | +$24.2M |
|
2
Sanofi
SNY
$121B
| $23.6M | 3.76% | 409,515 -40,000 | -9% | -$2.31M |
|
3
BridgeBio Pharma
BBIO
$9.89B
| $21.5M | 3.41% | 842,644 -67,426 | -7% | -$1.72M |
|
4
Syndax Pharmaceuticals
SNDX
$1.41B
| $19.9M | 3.17% | 1,034,846 +212,799 | +26% | +$4.1M |
|
5
Amazon
AMZN
$2.44T
| $19.7M | 3.13% | 105,607 +4,175 | +4% | +$778K |
|
6
Meta Platforms (Facebook)
META
$1.86T
| $16.8M | 2.67% | 29,316 -4,123 | -12% | -$2.36M |
|
7
Sarepta Therapeutics
SRPT
$1.78B
| $15.7M | 2.5% | 125,846 +42,187 | +50% | +$5.27M |
|
8
AstraZeneca
AZN
$248B
| $14.8M | 2.36% | 190,060 | – | – |
|
9
Microsoft
MSFT
$3.77T
| $14.4M | 2.29% | 33,427 +500 | +2% | +$215K |
|
10
Celldex Therapeutics
CLDX
$1.47B
| $14.2M | 2.27% | 419,103 +109,838 | +36% | +$3.73M |
|
11
Apple
AAPL
$3.45T
| $14.2M | 2.26% | 60,847 -653 | -1% | -$152K |
|
12
Nice
NICE
$8.73B
| $13.6M | 2.17% | 78,361 -3,100 | -4% | -$538K |
|
13
Kura Oncology
KURA
$686M
| $11.9M | 1.9% | 610,087 -739 | -0.1% | -$14.4K |
|
|
14
Cytokinetics
CYTK
$4.23B
| $11.9M | 1.89% | 225,021 -159,903 | -42% | -$8.44M |
|
15
Eli Lilly
LLY
$657B
| $11.7M | 1.86% | 13,190 | – | – |
|
16
Johnson & Johnson
JNJ
$427B
| $11.3M | 1.8% | 69,831 | – | – |
|
17
Ultragenyx Pharmaceutical
RARE
$2.89B
| $10.9M | 1.73% | 195,349 -98,483 | -34% | -$5.47M |
|
|
18
Nova
NVMI
$7.74B
| $10.8M | 1.72% | +51,960 | New | +$10.8M |
|
19
Novo Nordisk
NVO
$251B
| $9.3M | 1.48% | 78,080 | – | – |
|
20
Tower Semiconductor
TSEM
$6.58B
| $9.27M | 1.48% | 209,441 +59,841 | +40% | +$2.65M |
|
|
21
Praxis Precision Medicines
PRAX
$958M
| $8.76M | 1.39% | 152,307 -131,117 | -46% | -$7.54M |
|
|
22
Viking Therapeutics
VKTX
$3.04B
| $8.42M | 1.34% | +133,066 | New | +$8.42M |
|
|
CYBN
23
Cybin
CYBN
$176M
| $8.3M | 1.32% | 933,225 -24,648,170 | -96% | -$219M |
|
24
Immatics
IMTX
$619M
| $8.23M | 1.31% | 721,111 -10,000 | -1% | -$114K |
|
25
Pharvaris
PHVS
$1.39B
| $8.14M | 1.29% | 439,292 +36,027 | +9% | +$667K |
|